pharmaceutical investing EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437
G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
Term Sheet to Treat Colorado Project Uranium Waste Dumps and Gross Revenue Sharing Agreement with DISA Technologies
